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Endovascular aortic aneurysm repair via the left
ventricular apex of a beating heart
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An elderly man presented with a ruptured aortic arch, left lung compression, and hemoptysis. Multiple com-
orbidities and inadequate aortoiliac access disqualified him from conventional open repair or hybrid retrograde
transarterial thoracic endovascular aortic repair (TEVAR). Because our center has recently reported that a thoracic aortic
endograft can be successfully placed through the apex of the LV of a beating heart in a pig model, we received approval
for the compassionate use of antegrade transapical TEVAR (TaTEVAR) with bilateral femoral–carotid revascularization
to repair the aortic arch. As in our animal model, TaTEVAR was performed with accuracy and minimal hemodynamic
compromise. The patient was quickly weaned from inotropic and respiratory support postoperatively and was neurolog-
ically intact, but died on the tenth postoperative day from respiratory failure. ( J Vasc Surg 2009;49:759-62.)Our center has recently reported that an aortic en-
dograft can be placed through the left ventricle (LV) of a
beating heart and into the descending thoracic aorta of a
pig with a reasonable degree of accuracy and minimal
physiologic compromise.1 We concluded that thoracic en-
dovascular aortic repair (TEVAR) through the apex of the
LVmight be considered for patients with severe aortic, iliac
and femoral artery occlusive disease, life-threatening pa-
thology of the thoracic aorta that is otherwise amenable to
endovascular repair and normal aortic valve function.1 Of-
fered here is the first clinical report of TEVAR using ante-
grade aortic access via the LV of a beating heart.
CASE REPORT
A hypertensive, 79-year-old man, kyphotic, weighing 42 kg,
and on hemodialysis, presented with chest pain and shortness of
breath of 1 week’s duration. Computed tomography angiography
(CTA) of the head, neck, chest, abdomen and pelvis revealed (1) a
7.0-cm false aneurysm arising from a broad-based defect in the wall
of the transverse aortic arch, abutting the upper sternum and
compressing the left lung (Fig 1), (2) a normal ascending aortic
arch 30 mm in diameter, (3) a normal proximal descending tho-
racic aorta 24 mm in diameter, (4) a 90% ostial stenosis of the right
subclavian artery, (5) a patent infrarenal aorta, 1 cm in diameter,
with a porcelain wall, (6) heavily calcified iliac and femoral arteries,
patent, but with diameters too small for retrograde delivery of a
thoracic endograft, (7) minimal carotid and vertebral artery disease
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chest wall, remote from the false aneurysm.
Transesophageal echocardiography (TEE) revealed moder-
ate aortic stenosis with an aortic valve (AV) cross-sectional area
of 1.3 cm2, and mild aortic insufficiency. LV systolic function
was mildly depressed.
The patient soon developed worsening chest pain with he-
moptysis. The limited therapeutic options available were discussed
with the patient and his family. Two consulting cardiac surgeons
rejected conventional aortic repair under circulatory arrest owing
to the patient’s advanced age and comorbidities. Palliative therapy
was offered, but rejected by the patient and family. Carotid artery
revascularization off the ascending aorta with antegrade transaortic
TEVAR was not proposed for the certainty of entering the false
aneurysm upon sternotomy. Cervical carotid revascularization off
the femoral arteries would be necessary to allow an endovascular
repair of the aortic arch, but retrograde TEVAR was not proposed
because this would have required sewing a conduit to a heavily
calcified aorta. Furthermore, given the modest calibre of the aorta,
retrograde aortic passage of graft delivery sheaths and catheters
might have critically reduced perfusion to the femoral arteries,
compromising cerebral perfusion.
With our experimental knowledge of the feasibility of endograft
delivery through the LV apex1 and clinical experience in transapical
AV replacement,2-4 carotid revascularization through the femoral
arteries, with subsequent transapical TEVAR (TaTEVAR), appeared
to offer a therapeutic option for this patient. Our institution’s
ethicist was consulted and agreed that a compassionate attempt at
TaTEVAR was valid.
Procedure. This procedure was performed in a hybrid oper-
ating room with fixed-unit fluoroscopic capability. TEE monitor-
ing was used throughout the case. Despite the presence of hemop-
tysis, single-lumen endotracheal intubation was used to avoid
the need for left bronchial intubation andpossible rupture into the false
aneurysm. External defibrillating pads were placed on the chest,
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elevated to facilitate thoracotomy.
Extra-anatomic bypass. Bilateral carotid revascularization
was performed via the femoral arteries to provide secure cerebral
perfusion. The femoral vessels were exposed through oblique
groin incisions, the right common carotid artery through a vertical
incision low in the neck, and the left carotid, subclavian and axillary
arteries through standard incisions.
A 6-mm externally supported expanded polytetrafluoroethyl-
ene (ePTFE) graft (W.L. Gore and Associates, Flagstaff, Ariz) was
tunnelled from the right groin to pass somewhat laterally under the
clavicle before turning medially to the right common carotid
artery. The right subclavian artery was rejected as the recipient
artery for this graft because of a tight ostial stenosis.
On the left side, a femoral endarterectomy with axillofemoral
and carotid-subclavian bypass grafting was performed using exter-
nally supported 8-mm ePTFE grafts. The left common carotid
artery was ligated with a laparoscopic vascular stapler (1 Endopath
ETS Flex 45 No Knife Endoscopic Articulating Linear Stapler,
Ethicon Endo-Surgery Inc, Cincinnati, Ohio) just caudal to the
subclavian artery graft, ensuring that left carotid artery perfusion
now arose from the left femoral artery and not from antegrade flow
off the aortic arch.
Antegrade right carotid perfusion was occluded by retrograde
placement of an Amplatzer vascular plug (AGA Medical Corp,
Plymouth, Minn) at the origin of the brachiocephalic artery,
through the hood of the right carotid artery graft, ensuring that
right carotid artery perfusion now also arose from the ipsilateral
femoral artery. The origin of the left subclavian artery was similarly
occluded by retrograde placement of an Amplatzer plug through
the subclavian hood of the carotid–subclavian graft. Occlusion of
antegrade flow off the arch vessels was designed to prevent type II
endoleaks subsequent to TaTEVAR.
Transapical TEVAR. A 5-cm incision was made in the sixth
intercostal space overlying the LV apex as identified by fluoros-
copy. The pleura was opened and a nontraumatic Alexis wound
retractor (Applied Medical, Rancho Santa Margarita, Calif) was
applied. Pericardial fat was excised, followed by a pericardotomy
Fig 1. Computed tomography angiography demonstrates a large
false aneurysm off the aortic arch, abutting the sternum and
compressing the left lung.exposing the LV apex. Two paired orthogonal felt-pledgetedU-shaped 3-0 polypropylene sutures were placed into the LV apex
and secured with Rummel tourniquets. Temporary epicardial pac-
ing wires were placed directly onto the LV.
The LV was cannulated through this purse-string of sutures,
and a Bentson wire (Cook Inc, Bloomington, Ind) was advanced
past the AV under fluoroscopy. A 6F Pinnacle sheath (Terumo
Medical Corp, Elkton, Md) was placed past the AV. An exchange
technique was used to advance a Lunderquist wire (Cook Inc) to
the bifurcation of the abdominal aorta. A multimarker pigtail
catheter was placed through the hood of the left femoral graft to
the aortic root, and an arch aortogram was performed with 45° left
anterior oblique projection to define the extent of the aneurysm.
On the basis of preoperative and intraoperative imaging, a
TAG TG3415 thoracic endoprosthesis (W. L. Gore and Associ-
ates) was chosen for implantation. This graft measures 34 mm in
diameter and 15 cm in length and requires a 22F introducer
sheath. The existing transapical sheath was exchanged for the
introducer sheath (Fig 2), which was placed solely in the LV,
leaving only the Lunderquist wire to span the AV. Both introducer
placement and hemostasis at the LV access site were ensured with
tension on the Rummel tourniquets.
Under fluoroscopy, the undeployed graft was passed “bare-
back” beyond the delivery sheath in the LV (Fig 3), through the
AV, and positioned in the aortic arch to ensure at least 3-cm sealing
zones in the ascending and proximal descending thoracic aorta.
The graft navigated the aortic arch with ease. Rapid LV pacing was
used for all graft deployments and balloon inflations to augment
the accuracy of graft positioning. Reliable ventricular capture was
ensured at a rate of 140 to 180 beats/min with a reduction in
systolic blood pressure (SBP) to 60 mm Hg.
The graft was deployed and a repeat aortogram revealed
accurate placement and the presence of a proximal type I endoleak.
Balloon (Gore Tri-Lobe Balloon Catheter, W.L. Gore and Asso-
ciates) tamping of the proximal and distal sealing zones failed to
resolve the endoleak. A second, larger TAG endograft (40 mm 
10 cm) was deployed within the first graft to extend the coverage of
Fig 2. A 22F sheath has been introduced into the left ventricle
apex, through orthogonally placed felt pledgeted U-shaped
sutures.the ascending aorta by 2 cm. Care was taken not to cover the
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required upsizing of the introducer sheath to 24F, which was
tolerated well.
Repeat angiography confirmed resolution of the type I en-
doleak and continued patency of the adjacent coronary arteries
Fig 3. An angiogram demonstrates an introducer sheath in the
left ventricle, containing the TAG endograft about to be passed
“bareback” across the aortic valve.
Fig 4. A completion angiogram reveals the repaired aortic arch
false aneurysm with patent coronary arteries.(Fig 4). No flow was seen in the false aneurysm sac on TEE. A typeII endoleak from the brachiocephalic artery was suspected on
angiography. Owing to hypothermia and a coagulopathy that
developed intraoperatively, we decided to treat this endoleak con-
servatively with patient rewarming and normalization of his coag-
ulation profile.
All hardware was removed, and LV closure was obtained by
securing the apical sutures upon removal of the 24F introducer
sheath. A chest tube was placed in the left thoracic cavity and
brought out through the thoracotomy incision. All incisions were
closed in the standard fashion.
Physiologic parameters. The SBP decreased from 180 to
120 mm Hg upon induction of anesthesia. The SBP further
dropped to 90 mmHg upon guidewire crossing of the AV and was
maintained at 100 to 110 mm Hg with low-dose inotropic sup-
port. No additional hemodynamic effects were noted with passage
of the graft and delivery catheter across the AV. SBP predictably
dropped to60 mmHg with rapid LV pacing and rose quickly to
baseline between pacing episodes. Mild preoperative aortic insuf-
ficiency became moderate to severe with wire instrumentation
across the AV, but returned to baseline postoperatively. No signif-
icant change was noted in LV systolic function during or after the
procedure, as measured by TEE.
The procedure required 8.5 hours of operative time. The
TaTEVAR component of the procedure—including accessing the
LV apex—lasted 75 minutes and required 19.5 minutes of fluoros-
copy time and 450 mL of intravenous contrast (Optiray 320, Tyco
Healthcare, Montreal, Quebec, Canada). The remaining surgical
time was invested in constructing extra-anatomic bypasses, occlud-
ing the branch vessels off the aortic arch, and wound closure in a
small, kyphotic, atherosclerotic, and coagulopathic patient with
suboptimal positioning.
Blood loss was measured at 4000 mL, requiring the transfu-
sion of 12 U packed red blood cells, 1.5 U cell-saved blood, 12 U
fresh-frozen plasma, and 2 U of platelets. The patient’s lowest
recorded core-body temperature was 30.2°C.
On the first postoperative day, inotropic support was with-
drawn and the hypothermia and coagulopathy corrected. The
patient was extubated on the second postoperative day, and was
free of chest pain and neurologically intact. A CTA confirmed a
type II endoleak with 90% thrombosis of the false aneurysm sac
and extrinsic collapse of the left lung. No increase in the false
aneurysm size was noted compared with preoperative imaging.
The patient was soon transferred to the floor in stable condi-
tion. He died on postoperative day 10 from progressive respiratory
failure. Permission for autopsy was not granted.
DISCUSSION
We used transapical LV access to facilitate accurate
endovascular repair of a thoracic aortic aneurysm with
minimal physiologic compromise. The feasibility of clinical
TaTEVAR was suggested by the favorable anatomic and
physiologic results reported in our pigmodel for transapical
endografting.1 Our clinical and laboratory experience with
transapical endografting has shown that (1) accurate graft
deployment is possible, (2) the hemodynamic effect of
instrumentation across the AV does not limit the success
of the procedure, (3) there is no effect on postoperative AV
or LV function, and (4) secure LV closure is achieved.
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quired prolonged crossing of a 2.8-cm2 AV with an 18F
deliver sheath.1 However, this valve area/sheath size ratio
would not have reflected the clinical scenario described had
an even larger sheath been used to cross a smaller AV.
Instead, the Gore TAG endografts used are of low profile
when undeployed and are able to cross the AV with only a
13F delivery catheter spanning the AV. This enabled
TaTEVAR to be performed successfully, despite a moderately
stenotic AV. Furthermore, antegrade aortic placement of a
TAG endograft should not adversely effect graft migration,
because in vivo and in vitro testing suggests that the orien-
tation of the wires on the abluminal surface of the graft does
not effect graft fixation (personal communication with
Thoracic Product Specialist, W. L. Gore and Associa-
tes Inc).
In addition to valvular and ventricular dysfunction, a
potential risk of transapical access is LV access site bleeding.
However, surgical experience with transapical AV replace-
ment and LV venting for mitral valve commissurotomy
suggests that this access site can be managed safely.2 Three
of 60 patients undergoing transapical AV replacement at
our center experienced LV access site bleeding that re-
quired extensive suture repair and transfusion. All apical
bleeding was noted and treated intraoperatively. There
were no recognized cases of delayed postoperative bleeding
from the LV apex (unpublished data).
Clinically, transapical access provided a remarkably
stable platform for TaTEVAR. Furthermore, although
transapical access was attempted as a method of last resort,
sound angiographic principles suggest distinct advantages
to this approach compared with traditional retrograde ac-
cess for TEVAR. These advantages include (1) a short
working distance between the access site and the lesion to
be treated, (2) the ability to gain abundant guidewire
purchase distal to the intervention site, and (3) the ability tosnare a transapically placed guidewire from a femoral access
site and place it on tension to facilitate endografting across a
difficult aortic arch. Although antegrade transaortic access
can offer these advantages, it does not enable endovascular
grafting of the ascending arch adjacent to the coronary
arteries, as described in this report.
Such advantages may prove to expand the practice of
TaTEVAR beyond the confines of patients with inadequate
retrograde arterial access. Further investigation of the clin-
ical applicability of TaTEVAR is warranted.
CONCLUSION
This is the first clinical report of TEVAR performed
through the LV apex of a beating heart. Transapical
TEVAR was performed with accuracy and minimal hemo-
dynamic compromise, despite the presence of moderate
aortic stenosis.
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